The Effects of oXiris in Cardiogenic Shock Requiring VA-ECMO (CLEAN ECMO)
Cardiogenic Shock
About this trial
This is an interventional treatment trial for Cardiogenic Shock
Eligibility Criteria
Inclusion Criteria: Patients with more than 18 years old CS is defined as the presence of the following: 2-1) Systolic blood pressure is less than 90 mmHg for more than 30 minutes despite the fluid therapy, or the use of pressure boosting agents to maintain the systolic blood pressure more than 90 mmHg. 2-2) Peripheral hypoperfusion (cold skin, urine less than 30 cc per hour, impaired consciousness, lactate ≥2.0 mmol/l) or a person with pulmonary edema. 2-3) Causes of CS include ischemic (acute myocardial infarction or ischemic cardiomyopathy, shock during percutaneous coronary intervention), myocardial (end-stage heart failure, myocarditis), post-cardiotomy shock, cardiac tamponade, or pulmonary thromboembolism. Patients receiving VA ECMO owing related to the causes listed in 2-1, 2-2, 2-3. Written informed consent from patient or legal surrogates Exclusion Criteria: Other causes except for CS: septic shock, cardiac arrest by serious ventricular arrhythmia mot related to the myocardial ischemia or heart failure. Shock with unwitnessed cardiac arrest outside the hospital Severe non-cardiac morbidity with expected survival less than 6 months (malignancy, respiratory failure) Suspicious of brain death Those who refused active treatment body weight under 30 kg Heparin allergy
Sites / Locations
- Samsung Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Intervention
Control
Oxiris for 24 h
Usual care